Airain ltd bought a new position in shares of Bristol-Myers Squibb Company (NYSE:BMY) in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 9,461 shares of the biopharmaceutical company’s stock, valued at approximately $527,000.

A number of other large investors have also modified their holdings of the business. State Street Corp boosted its position in Bristol-Myers Squibb by 1.8% during the first quarter. State Street Corp now owns 68,893,779 shares of the biopharmaceutical company’s stock worth $3,746,446,000 after purchasing an additional 1,223,457 shares during the period. Jennison Associates LLC boosted its position in Bristol-Myers Squibb by 5.4% during the second quarter. Jennison Associates LLC now owns 23,118,789 shares of the biopharmaceutical company’s stock worth $1,288,179,000 after purchasing an additional 1,184,652 shares during the period. Ameriprise Financial Inc. boosted its position in Bristol-Myers Squibb by 18.7% during the first quarter. Ameriprise Financial Inc. now owns 15,547,051 shares of the biopharmaceutical company’s stock worth $845,504,000 after purchasing an additional 2,451,390 shares during the period. Legal & General Group Plc boosted its position in Bristol-Myers Squibb by 2.7% during the second quarter. Legal & General Group Plc now owns 8,431,348 shares of the biopharmaceutical company’s stock worth $469,802,000 after purchasing an additional 217,920 shares during the period. Finally, Swiss National Bank boosted its position in Bristol-Myers Squibb by 27.2% during the first quarter. Swiss National Bank now owns 5,921,670 shares of the biopharmaceutical company’s stock worth $322,020,000 after purchasing an additional 1,267,900 shares during the period. Hedge funds and other institutional investors own 69.14% of the company’s stock.

A number of equities analysts have weighed in on BMY shares. Deutsche Bank AG set a $55.00 target price on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a research report on Monday, July 17th. Vetr downgraded shares of Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating and set a $61.66 price target on the stock. in a report on Tuesday, July 25th. BMO Capital Markets reissued an “underperform” rating and issued a $47.00 price target (down from $51.00) on shares of Bristol-Myers Squibb in a report on Wednesday, July 26th. Piper Jaffray Companies set a $60.00 price target on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Thursday, July 27th. Finally, Leerink Swann lowered their price target on shares of Bristol-Myers Squibb from $66.00 to $61.00 and set an “outperform” rating on the stock in a report on Friday, July 28th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $64.93.

In other Bristol-Myers Squibb news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction that occurred on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now directly owns 46,297 shares in the company, valued at $2,777,820. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.23% of the stock is owned by company insiders.

Bristol-Myers Squibb Company (NYSE BMY) opened at $60.86 on Friday. Bristol-Myers Squibb Company has a 52-week low of $46.01 and a 52-week high of $66.10. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. The company has a market cap of $101,459.04, a P/E ratio of 20.94, a price-to-earnings-growth ratio of 2.44 and a beta of 1.18.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). Bristol-Myers Squibb had a net margin of 20.56% and a return on equity of 32.41%. The business had revenue of $5.25 billion for the quarter, compared to the consensus estimate of $5.20 billion. During the same quarter in the previous year, the business earned $0.77 earnings per share. The firm’s revenue was up 6.7% on a year-over-year basis. equities research analysts predict that Bristol-Myers Squibb Company will post 2.99 EPS for the current fiscal year.

The firm also recently declared a quarterly dividend, which was paid on Wednesday, November 1st. Shareholders of record on Friday, October 6th were given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date was Thursday, October 5th. Bristol-Myers Squibb’s payout ratio is currently 61.42%.

TRADEMARK VIOLATION NOTICE: “Airain ltd Takes $527,000 Position in Bristol-Myers Squibb Company (BMY)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally copied and republished in violation of United States and international trademark & copyright laws. The original version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/11/11/airain-ltd-takes-527000-position-in-bristol-myers-squibb-company-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.